Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some safety-related claims (general bleeding risk) align with the label excerpt, but multiple claims are either unsupported or go beyond the provided label excerpts (e.g., non-prescribing/illegitimate pharmacy statements, specific urgent-care triggers, and detailed interaction examples).
Category Scores
Accurate Statements
Clopidogrel increases bleeding risk.
Section 5.2 — 'P2Y12 inhibitors... including clopidogrel tablets, increase the risk of bleeding.'
Clopidogrel can cause serious bleeding, including gastrointestinal bleeding.
Section 5.2 — 'increase the risk of bleeding' (label excerpt provided does not explicitly mention GI bleeding, so this is only partially supported).
Aspirin or other antiplatelet drugs can raise bleeding risk when used with clopidogrel.
Section 5.2 — general statement that P2Y12 inhibitors including clopidogrel increase bleeding risk (no explicit aspirin/antiplatelet combination stated in provided excerpt).
Anticoagulants (for example, warfarin, apixaban, rivaroxaban) can raise bleeding risk when used with clopidogrel.
Section 5.2 — general bleeding risk for P2Y12 inhibitors (no explicit anticoagulant examples stated in provided excerpt).
NSAIDs (for example, ibuprofen, naproxen), depending on the regimen, can raise bleeding risk when used with clopidogrel.
Section 5.2 — general bleeding risk for P2Y12 inhibitors (no explicit NSAID examples stated in provided excerpt).
Unsupported Statements
Clopidogrel 75 mg is a prescription medicine in most countries.
No such statement appears in the provided label excerpts.
Legit online pharmacies typically require a prescription (often after brief verification).
Not supported by the provided label excerpts.
Buying clopidogrel from unverified sites can raise risks such as counterfeit tablets, incorrect dosage, or medicines stored improperly.
Not supported by the provided label excerpts.
Clopidogrel is commonly dosed once daily at the 75 mg strength.
The provided label excerpts do not include dosing frequency or administration instructions for 75 mg.
Clopidogrel can cause bruising that’s more than expected.
The provided label excerpts mention bleeding risk generally but do not include bruising as an adverse reaction or severity qualifier.
Seek urgent care if taking clopidogrel and experiencing black/tarry stools.
The provided label excerpts do not include specific symptom-based urgent-care instructions.
Seek urgent care if taking clopidogrel and experiencing vomiting blood.
The provided label excerpts do not include specific symptom-based urgent-care instructions.
Seek urgent care if taking clopidogrel and experiencing severe unexplained weakness.
The provided label excerpts do not include specific symptom-based urgent-care instructions.
Seek urgent care if taking clopidogrel and experiencing signs of major bleeding.
The provided label excerpts do not include specific instruction language about seeking urgent care for major bleeding.
Aspirin or other antiplatelet drugs can raise bleeding risk when used with clopidogrel.
Provided excerpt supports only general bleeding risk of P2Y12 inhibitors; it does not specifically mention aspirin/antiplatelets or combination-induced bleeding.
Anticoagulants (for example, warfarin, apixaban, rivaroxaban) can raise bleeding risk when used with clopidogrel.
Provided excerpt supports only general bleeding risk; it does not specifically mention anticoagulants or those examples.
NSAIDs (for example, ibuprofen, naproxen), depending on the regimen, can raise bleeding risk when used with clopidogrel.
Provided excerpt supports only general bleeding risk; it does not specifically mention NSAIDs or those examples.
Contradictions
Low
AI Statement
Clopidogrel is commonly dosed once daily at the 75 mg strength.
Label Reference
Provided label excerpts do not state this; no direct contradiction can be confirmed from the excerpts.
Important Omissions
Avoidance of omeprazole/esomeprazole specifically due to CYP2C19 inhibition (and reduced antiplatelet activity), including the 'avoid concomitant use' instruction.
Importance:
Moderate
Mention of CYP2C19 poor metabolizers and consideration of another P2Y12 inhibitor per boxed warning/Section 12.5.
Importance:
Moderate
Use/avoidance guidance regarding strong CYP2C19 inducers to prevent reduced effectiveness (Section 5.2).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
General bleeding-risk statements are directionally consistent, but symptom-specific urgent-care instructions and several interaction claims are not supported by the provided label excerpts; additionally, key on-label interaction guidance for CYP2C19 inhibitors (omeprazole/esomeprazole) is omitted.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are not supported by the provided clopidogrel label excerpts, and key on-label CYP2C19 interaction warnings are omitted.
Suggested Improvement
Limit statements to on-label points present in the label excerpts (general bleeding risk; CYP2C19-related diminished effect and avoidance of omeprazole/esomeprazole) and remove or qualify unsupported pharmacy/symptom/interaction examples not present in the provided prescribing information.